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ABSTRACT 
To understand the mechanism of cellular stress in basal-parabasal layers of normal cervical 
epithelium and during different stages of cervical carcinoma, we analyzed the alterations 
(expression/methylation/copy-number variation/mutation) of HIF-1α and its associated genes 
LIMD1, VHL and VEGF in disease free normal-cervix (n=9), adjacent normal-cervix of tumors 
(n=70), CIN (n=32), CACX (n=174) samples and two CACX cell lines. In basal-parabasal 
layers of normal cervical epithelium, LIMD1 showed high protein expression while low protein 
expression of VHL was concordant with high expression of HIF-1α and VEGF irrespective of 
HPV16 infection. This was in concordance with the low promoter methylation of LIMD1 and 
high in VHL in the basal-parabasal layers of normal-cervix. LIMD1 expression was significantly 
reduced while VHL expression was unchanged during different stages of cervical carcinoma. 
This was in concordance with their frequent methylation during different stages of this tumor. In 
different stages of cervical carcinoma, the expression pattern of HIF-1α and VEGF was high as 
seen in basal-parabasal layers and inversely correlated with the expression of LIMD1 and VHL. 
This was validated by demethylation experiments using 5-aza-dC in CACX cell lines.   
Additional deletion of LIMD1 and VHL in CIN/CACX provided an additional growth advantage 
during cervical carcinogenesis through reduced expression of genes and associated with poor 
prognosis of patients.  
Our data showed that overexpression of HIF-1α and its target gene VEGF in the basal-
parabasal layers of normal-cervix was due to frequent inactivation of VHL by its promoter 
methylation. This profile was maintained during different stages of cervical carcinoma with 
additional methylation/deletion of VHL and LIMD1.  
Abbreviations: CACX: cervical carcinoma; CIN: cervical intraepithelial neoplasia; FIGO: 
International Federation of Gynecology and Obstetrics; HPV: human papillomavirus; HNSCC: 
Head and neck squamous cell carcinoma; LCM: Laser capture microdissection; IHC: 
immunohistochemistry; ICC: immunocytochemistry; PCR: Polymerase chain reaction; LOH: 
loss of heterozygosity; MA: microsatellite size alteration; MSRA: methylation sensitive 
restriction analysis; MSP: Methylation specific PCR; PBL: peripheral blood lymphocytes; 








Cancer of uterine cervix (CACX) stands as the third most common cancer among women 
accounting for about 9% of all the cancer affected cases worldwide (1). In India, CACX is the 
second most frequent cancer (incidence rate: 20.2 in 1,00,000) among females (2). Apart from 
other etiological factors, persistent infection by high risk-Human papilloma virus (hr-HPV 16, 
18, 33) is the primary cause of CACX (3). It has been suggested that hr-HPV infection in the 
basal stem cells of squamocolumnar junction of the normal-cervix induces some cellular stress, 
resulting in changes in cellular differentiation/proliferation and induction of cellular 
transformation (4,5). Among different stress response genes, HIF-1α expression is highly 
increased in CIN/CACX compared to its expression in normal-cervix (6). The stability of HIF-1α 
is regulated by the tumor suppressor genes LIMD1 and its interacting partner VHL (7). Low 
expression of VHL is observed in basal-parabasal layers of normal cervical epithelium and 
CACX (8), However to date, no studies have investigated LIMD1 expression in normal cervix 
and CACX. On the contrary, high/medium expression of HIF-1α transcriptional target, VEGF 
was reported in basal-parabasal layers of normal-cervix and in CIN/CACX (6). 
The molecular profiles of LIMD1, VHL, HIF-1α and VEGF have not been analyzed within the 
same set of basal-parabasal and spinous layers of normal-cervix and primary cervical lesions 
to decipher if deregulation of this pathway is evident in different stages of this disease. 
Herein, we analyzed the protein expression of LIMD1, VHL, HIF-1α and VEGF through 
immunohistochemistry/immunocytochemistry in normal-cervix, cervical lesions at different 
clinical stages and CACX cell lines. Furthermore, we also investigated epigenetic promoter 
methylation changes of LIMD1 and VHL in basal-parabasal and spinous layers of normal-
cervix, cervical lesions and CACX cell lines. Finally, copy number variation/mutation analyses 
of LIMD1, VHL and HIF-1α in the primary cervical lesions were performed and correlated with 
the alterations of these genes with different clinicopathological parameters.    
Our data revealed that VHL was frequently inactivated by epigenetic silencing in the basal-
parabasal layers of normal cervical epithelium, and this might be the driver of over-expression 
of HIF-1α and its target gene VEGF. This profile was maintained during different stages of 
CACX along with additional methylation/deletion of VHL and LIMD1. 
 
Material and Methods 
 
Collection of Clinical specimens 
 
A) Freshly operated/biopsy samples of 32 CIN (11 low-grade CIN I and the rest high-grade CIN 
II/III) and 174 primary CACX lesions (77 stage I/II and 97 stage III/IV tumors) (Fig S1) as well 
as corresponding normal tissues accompanied with corresponding peripheral blood 
lymphocytes (PBLs) were collected from the hospital section of Chittaranjan National Cancer 
Institute (CNCI), Kolkata, India after appropriate approval of the Institutional Ethical Committee 
and informed consent from the patients. In addition, normal cervical tissues (disease free) 
(n=9) were collected from patients who underwent radical hysterectomy due to other 
gynecological abnormalities from the hospital section of CNCI, Kolkata, India after appropriate 
approval of the Institutional Ethical Committee and informed consent from the patients  (FigS1). 
Part of the freshly operated tissues were paraffin embedded after formalin fixation for 
immunohistochemical analyses and another part of those operated tissues and respective 
PBLs were frozen immediately after collection at -80°C until use. The tumors were graded and 
staged according to International Federation of Gynecology and Obstetrics (FIGO) 
classification.    
B) PBLs (Peripheral blood lymphocytes) were also collected from 220 unrelated individuals 
(control subjects) without any history of CACX with informed consent and stored at -80°C until 
use.  
C) The CACX cell lines HeLa and SiHa were purchased from National Centre for Cell 
Sciences, Pune, India and grown in accordance with the supplier’s instructions. 
Microdissection and DNA extraction 
A) The contaminant normal cells in the cervical lesions were removed by microdissection from 
cryosections (5μm) using surgical knives under a dissecting microscope (Leica MZ16, 
Germany).  The representative sections from different regions of the specimens were stained 
with hematoxylin and eosin (H&E) and then examined by senior pathologist for diagnosis as 
well as for marking of the dysplastic epithelium/tumor rich regions. The samples containing 
>70-80% dysplastic epithelium/tumor cells were taken for isolation of high-molecular-weight 
DNA by proteinase-K digestion followed by phenol-chloroform extraction according to standard 
procedure (9, 10). Similarly, DNA from normal cervical tissues (disease free), 
histopathologicaly adjacent normal cervical epitheliums and blood were also isolated. 
B) In order to investigate promoter methylation pattern of LIMD1 and VHL in different layers of 
histopathologicaly normal cervical epithelium, microdissection of the basal-parabasal and 
spinous layers were done in paraffin/cryosections of HPV16 negative normal-cervix (disease 
free) (n=9), HPV16 positive (n=23) and HPV16 negative (n=15) histopathologicaly normal-
cervix adjacent to CACX by laser capture microdissection (LCM) microscope (Zeiss 
Palm/Apotome, Germany). DNA from the microdissected samples were isolated by standard 
procedure (FigS1). (9,10,11). 
Detection of HPV-16 and HPV-18 
HPV infection was detected by PCR using MY09 and MY11 primers, in normal cervical 
epitheliums, primary cervical lesions and CACX cell lines HeLa and SiHa (11,12,13). This was 
followed by typing of HPV 16/18 using type specific primers and confirmed by southern blot 
hybridization as described previously (11,12,13).  
Expression analysis of LIMD1, VHL, HIF-1α and VEGF by 
immunohistochemistry/immunocytochemistry   
In order to study the protein expression pattern of LIMD1, VHL HIF-1α and VEGF, 
immunohistochemical analyses were done in HPV16 negative normal-cervix (disease free) 
(n=9), HPV16 positive (n=47) and HPV16 negative (n=15) histopathologicaly normal cervical 
epithelium adjacent to tumors, CIN (n=15) and primary CACX (n=55) samples according to the 
standard procedure (12). The tissue sections (paraffin embedded/cryosections) were reacted 
overnight with primary antibodies against LIMD1 (Dr. Tyson V. Sharp, Barts Cancer Institute, 
UK), VHL (sc-5575), HIF-1α (sc-53546) and VEGF (sc-507) from Santa Cruz Biotechnology, 
CA, USA at a dilution of 1:100 for LIMD1 and VHL and 1:80 for HIF-1α and VEGF at 4°C. HRP 
conjugated goat anti-rabbit (sc-2004) for LIMD1, VEGF and VHL and goat anti-mouse IgG (sc-
2005) for HIF-1α were added in 1:500 dilutions (21). For permanent staining of the primary 
tissues the slides were developed using 3-3’ diaminobenzidine as the chromogen and 
counterstained with hematoxylin. The final evaluation of expression was done according to 
Perrone et.al 2006 (14).   
For immunocytochemical (ICC) analysis, cover slip culture of HeLa and SiHa cell lines were 
reacted with the same dilution of primary antibody of these genes after permeabilisation with 
0.5% Triton X-100 and blocking with 3-5% BSA. After washing, the cover slips were incubated 
with FITC conjugated corresponding secondary antibody goat anti mouse (sc-2010) and goat 
anti rabbit (sc-2012) at 1:500 dilution and mounted with glycerol after thorough washing. 
Imaging of the cover slip was performed in florescence microscope (Leica DM4000 B, 
Germany). 
Promoter methylation analysis of LIMD1 and VHL 
LIMD1 and VHL promoter methylation status were analyzed in basal-parabasal and spinous 
layers of HPV16 negative normal-cervix (disease free) (n=9), HPV16 positive (n=23) and 
HPV16 negative (n=15) histopathologicaly normal-cervix adjacent to CACX, CIN (n=32) and 
primary CACX (n=174) samples by PCR-based methylation sensitive restriction analysis 
(MSRA) (FigS1) (Table S1) (15). Approximately, 100 ng of DNA samples were individually 
digested overnight with methylation-sensitive restriction enzymes HpaII (CCGG) (Promega, 
USA) and HhaI (GCGC) (Sibenzyme, Russia) separately. The 445 bp fragment of β-3A adaptin 
gene (K1) and 229 bp fragment of RARβ2 (K2) were used as digestion and integrity controls 
respectively (16). Mock digestion was done with each sample without any restriction enzyme. 
PCR products were analyzed on 2% agarose gels, visualized under UV illumination and 
photographed. 
To validate the methylation data of LIMD1 and VHL obtained by MSRA, methylation-specific 
PCR (MSP) in 28 paired cervical lesions and in HeLa and SiHa cell lines were done after 
bisulfite modification of the DNA by standard procedure (Table S2) (17). 
Validation of promoter methylation of LIMD1 and VHL in HeLa and SiHa cell lines 
In order to validate the inactivation of LIMD1 and VHL by promoter methylation,  HeLa and 
SiHa cell lines were grown in the absence and presence of different doses (5μM, 10μM and 
20μM) of demethylating agent 5-Aza-2’-deoxycytidine (5-aza-dC) for 5 days. RNA was 
prepared using TRIzol reagent and real time quantification of the LIMD1 and VHL expression 
were performed for mRNA expression as described earlier (Table S3) (12,18). β2-microglobulin 
was used as a control for equal loading and RNA integrity (Table S3).    
For immuno-fluorescence analysis after 5-aza-dC treatment, HeLa and SiHa cells were grown 
over night on cover slip and treated with 20 μm 5-aza-dC as described earlier (12,19). Then the 
cells were fixed with chilled methanol and used for immuno-fluorescence analysis. 
Copy number variation (CNV) analysis of LIMD1, VHL and HIF-1α  
Deletion analysis of LIMD1 and VHL  
Deletion analysis of LIMD1 and VHL were performed using 4 microsatellite markers (Ensembl 
release 83; Genome Database) in CIN (n=32) and CACX (n=174) samples by a standard PCR 
using a [γ-p32] ATP-labeled forward primer as described earlier (14) (Fig S1, Table S4). PCR 
products were electrophoresed on 7% denaturing polyacrylamide sequencing gel and 
autoradiographed (14). Loss of heterozygosity (LOH) was detected by densitometric scanning 
(Bio-Rad GS-800) and the scoring of LOH and microsatellite size alterations (MA) were done 
on autoradiogram as described previously (14). MA was detected as a shift in the mobility of 1 
(MA1) or both (MA2) alleles compared to their normal alleles. MA in 1 allele and loss in other 
allele was regarded as LOH+MA (LMA).      
Amplification analysis of HIF-1α 
A quantitative measurement of HIF-1α amplification was carried out using differential 
polymerase chain reaction (DPCR) method as per procedure (Fig S1, Table S4) (19). The 
dopamine D2 receptor (DRD2) was used as internal control gene for HIF-1α due to no report of 
alterations in CACX.  
Genotyping of hmLIMD1 
Since, hmLIMD1 microsatellite marker of LIMD1 locus is intragenic and highly polymorphic, 
containing twelve d(CA)n alleles and was previously reported to be associated with HNSCC risk 
(20), genotyping of hmLIMD1 was done in 206 primary cervical tumors and 220 unrelated 
normal individuals by amplifying d(CA)9-38 repeat in a standard PCR using [γP32] ATP-labeled 
forward primer as described above in order to find whether any of the (CA)n allele is associated 
with CACX risk. Signal intensities of radiolabelled products were measured by densitometric 
scanner (Bio-Rad, USA). The number of CA repeats was validated as described previously 
(20).  
Mutation analysis of LIMD1  
Mutation screening was done in the functional domains of LIMD1 viz., RB1 binding domain 
(Exon 1) and VHL binding domain (Exon 5) in CACX (n=63) samples by single-strand 
conformation polymorphism (SSCP) as per procedure (Table S5) (20). Random samples 
(n=10) were sequenced for validation by Sanger sequencing using 3130xl-Genetic Analyzer 
(Applied Biosystems, USA) (20). 
Statistical analysis  
Fisher’s exact test was used to determine different clinico-pathological association with tumors 
genetic alterations. All statistical tests were 2-sided and considered significant at probability 
value, P < 0.05. Survival curves were obtained according to Kaplan–Meier method. Overall 
survival (OS) was measured from the date of surgery to the date of most recent follow-up or 
death (up to 5 years). Multivariate Cox-proportional hazard regression model was used to test 
the statistical significance of potential prognostic factors. From this model we estimated the 
hazard ratio (HR) for each potential prognostic factor with a 95% confidence interval (CI). The 
detailed follow-up records were available for 58 CACX patients (Fig S1). All the statistical 
analyses were performed using statistical programs Epi Info 6.04, SPSS 10.0 (SPSS, Chicago, 
IL).   
Results 
Protein expression profile of LIMD1, VHL, HIF-1α and VEGF in normal cervical 
epithelium and primary cervical lesions  
In normal-cervix, there was no significant difference in expression of LIMD1 between basal-
parabasal layers and spinous layers (Table1, Fig1). In normal cervical epithelium, high/medium 
nuclear/cytoplasmic expression of LIMD1 in basal-parabasal layers (45-52%) (mean 48.33, 
S.D.± 3.51) was comparable to expression in the spinous layer (50-60%) (mean 55.33 , S.D. ± 
5.03) (Table1). LIMD1 expression was not altered in disease associated adjacent normal 
epithelium with HPV16 infection (Table1). However, reduced expression of LIMD1 was 
observed in CIN (69%) and CACX (72%) samples (mean 70.5, S.D.± 2.12) (Table1, S6; Fig1).    
In normal cervical epithelium, expression of VHL gradually increased from basal-parabasal 
layers to spinous layer in majority of the samples (Table1, Fig1). Low nuclear/cytoplasmic 
expression of VHL in basal-parabasal layers of the normal epithelium was seen in 71-75% 
(mean 73.3 , S.D. ±2.08) samples followed by 15-22% (mean 18.33, S.D.± 3.51) in the spinous 
layer irrespective of HPV16 infection (Table1, S2). Similar reduced expression pattern of VHL 
was seen in CIN (66%) and CACX (74%) (mean 70, S.D.± 5.65) (Table1, S6; Fig1).   
In normal epithelium, expression of HIF-1α gradually decreased from proliferating basal-
parabasal layers to differentiated spinous layer in majority of the samples irrespective of 
HPV16 infection (Table 1, Fig1). High/medium nuclear/cytoplasmic expression of HIF-1α in 
basal-parabasal layers was seen in 83-89% (mean 85.7, S.D.± 3.05) samples followed by 12-
25% (mean 19, S.D.± 6.55) samples in the spinous layer irrespective of HPV16 infection 
(Table1). Like high/medium expression pattern of HIF-1α in basal-parabasal layers of normal 
epithelium, its similar expression pattern was seen in CIN (76%) and CACX (78%) (mean 77 
,S.D.± 1.41) (Table1, S6; Fig1).    
In concordance to the expression of HIF-1α, high/medium membrane/cytoplasmic expression 
of VEGF in basal-parabasal layers was seen in 79-86% (mean 81.66 , S.D.± 3.78) samples 
followed by 16-23% (mean 18.33 , S.D.± 4.04) samples in the spinous layer irrespective of 
HPV16 infection (Table1). Like basal-parabasal layers of normal epithelium, high/medium 
expression of VEGF was seen in CIN (82%) and CACX (85%) samples (mean 83.5, S.D.± 2.12 
) (Table1, S6; Fig1). The concordances among the proteins are shown in Table S7.    
Promoter methylation pattern of LIMD1 and VHL in normal cervical epithelium and 
cervical lesions 
To identify a potential mechanism of LIMD1 and VHL expression in basal-parabasal layers of 
normal-cervix, their promoter methylation status were analyzed. In normal epithelium (n=79), 
promoter methylation of these genes was evident in 12-15% (mean 13.5, S.D.± 2.12) of normal 
cervical epithelium samples (Fig 2a,b). However, after microdissection of the normal epithelium 
(n=47), 28% promoter methylation of LIMD1 was seen in basal-parabasal layers comparable to 
32% in spinous layer (Fig2a). The methylation frequency of LIMD1 was high in CIN (41%) 
followed by significant increase in stage I/II tumors (65%) (p=0.006) and became comparable 
in stage III/IV tumors (68%) (mean 66.5 , S.D.± 2.12) (Fig2a).   
Unlike LIMD1, high frequency (60%) of promoter methylation of VHL was seen in the basal-
parabasal layers of normal-cervix compared to spinous layer (28%)  (Fig2b). Similarly, the 
methylation frequency of VHL was high in CIN (44%) and did not change significantly in stage 
I/II (50%) and stage III/IV (62%) tumors (Fig2b) (mean 52, S.D.± 9.16). Significant concordance 
was evident between MSRA and MSP techniques of promoter methylation analysis (Table S8). 
LIMD1 was methylated both in Hela and SiHa. VHL was methylated in Hela, but unmethylated 
in SiHa.    
Validation of promoter methylation of LIMD1 and VHL in HeLa and SiHa cells 
To confirm inactivation of the LIMD1 and VHL genes by promoter hypermethylation, their 
expressions were analyzed by quantitative RT-PCR after treatment of HeLa and SiHa cells with 
different doses (5μM, 10 μM, 20 μM) of 5-aza-dC. Dose dependent increased expression of 
LIMD1 and VHL were observed in the cell lines compared to untreated controls (Fig3a). 
Gradual upregulation in expression of LIMD1 was seen in the cell lines with increase in 
concentration of 5-aza-dC in accordance with promoter methylation (Fig3a).   
On the other hand, differential expression of VHL was seen in the cell lines with increase of 5-
aza-dC concentration in accordance with its methylation pattern. It’s expression was high in 
HeLa at 5μM 5-aza-dC followed by comparable level of expression with increase in 
concentration (Fig3a). However, in SiHa it’s expression was comparable to control at 5μM and  
10 μM 5-aza-dC followed by increase in expression at 20 μM concentration (Fig3a). The  
increase in m-RNA expression of LIMD1 and VHL in presence of 5-aza-dC in the cell lines was 
seen to be concordant with their increase in protein expression by ICC (Fig3a). In accordance 
with increase in LIMD1 and VHL expression, reduced nuclear/cytoplasmic expression of HIF-
1α and cytoplasmic/membrane expression VEGF were evident in the cell lines at 20 μm 5-aza-
dC concentration (Fig3b,c).    
CNV analysis of LIMD1, VHL and HIF1-α 
Differential deletion frequency of LIMD1 and VHL were seen during different stages of CACX 
(Fig 4, TableS9). In CIN, the deletion frequency of LIMD1 was 29% followed by significant 
increase in stage I/II tumors (49%; p value=0.01) with slight increase in stage III/IV tumors 
(63%) (Fig 4a, TableS9). The co-alterations of deletion and methylation of LIMD1 were seen in 
13% CIN and 28% CACX samples, indicating it as a candidate TSG of this tumor (Fig 4a, 
TableS9). On the other hand, infrequent MA (Microsatellite Alteration) in LIMD1 locus was seen 
in 5% samples (Fig 4a, TableS9). 
Unlike LIMD1, no deletion of VHL was seen in the CIN samples (Fig 4b TableS9). But the 
deletion frequency of VHL was significantly increased at stage I/II tumors (34%) and became 
comparable at stage III/IV tumors (38%) (Fig 4b, TableS9). The co-alterations of deletion and 
methylation of VHL was seen in 12% CACX samples (TableS9) indicating it as a candidate 
TSG. The deletion of LIMD1 and VHL showed concordance with their respective expressions in 
CIN (p=0.00002, p=0.00004) and CACX (p=0.000045, p=0.009) samples (TableS10). 
However, HIF-1α showed no amplification in same set of CIN and CACX samples (TableS9) 
indicating that the effects of increased HIF-1a expression observed may be due to inactivation 
of LIMD1 and VHL rather than increased gene expression of HIF-1a. 
Analysis of hmLIMD1 polymorphism and its association with CACX risk 
To identify susceptible allele for LIMD1, if any, associated with CACX risk, we analyzed allele 
polymorphism of hmLIMD1 marker in population based case-control study. A total of 12 CA 
repeat alleles were observed in our study population, ranging from 9 repeats [(CA)9] to 38 
repeats [(CA)38] (Table S11a). In case-control study the frequencies of (CA)19 and (CA)32 were 
significantly high in cases compared to control (Table S11a). Alleles (CA)19, (CA)20 , (CA)21 and 
(CA)24  were relatively common  (>10% frequency) both in cases and controls. In comparison to 
homozygous alleles distribution among cases and controls, significant association of 
[(CA)19/(CA)19] allele was seen with the cases (Table S11b). While alleles (CA)26 and (CA)38 
were rare in this study population (Table S11).   
Mutation Analysis of LIMD1  
In mutation analysis of LIMD1, Exon1 (containing the RB1 binding domain) and Exon5 
(containing the VHL binding domain) were examined. No band shifts were observed in SSCP 
analysis of the samples (0/63) and random sequencing of samples revealed no base changes 
(0/10) (Table S16), indicating mutation in LIMD1 may be a rare phenomenon in CACX.  .   
Clinicopathological Association with alterations of the genes  
In basal-parabasal layers of normal-cervix, LIMD1 showed low frequency (28%) of alteration 
(methylation) followed by gradual increase of its frequency of alterations (methylation/deletion) 
in CIN (47%) followed by significant increase in stage I/II tumors (80%) (p=0.003) and 
comparable in stage III/IV tumors (87%) (Fig 4c i). The alterations of LIMD1 were concordant 
with its reduced expression in CIN (p=0.02) and CACX (p=0.0000002) (Table S12). Also, 
alterations of LIMD1 showed concordance with high/medium expression HIF-1α and VEGF in 
CIN (p=0.03) and CACX (p=0.02) samples (Table S13).  
Unlike LIMD1, VHL showed high (60%) methylation in basal-parabasal layers of normal 
cervical epithelium and in CIN (44%) with a gradual increase in stages I/II tumors (59%) and 
stages III/IV tumors (70%) (Fig 4c ii). The alteration of VHL was concordant with its reduced 
expression in basal-parabasal layers of normal-cervix, CIN (p=0.01) and CACX (p=0.001) 
(Table S12, S14). Alterations of VHL showed concordance with high/medium expression of 
HIF-1α and VEGF in basal-parabasal layers of normal-cervix, CIN (p=0.006) and CACX 
(p=0.005) samples (Table S13). Significant concordance was seen between alterations of 
LIMD1 and VHL in CIN (p=0.03) and CACX (p=0.01), (Table S15, S16) suggesting additive 
effect of the alterations of these genes in development of invasive lesions of CACX. Significant 
poor overall survival (OS) was evident for CACX patients with simultaneous overall alterations 
of LIMD1, VHL and high/medium expression of HIF-1α, VEGF; indicating their prognostic 
importance (Figure 5).    
DISCUSSION   
The aim of this study was to investigate the changes in molecular profile of the genes; LIMD1, 
VHL, HIF-1α and VEGF at different stages of CACX.  
Immunohistochemistry revealed that high/medium expression of LIMD1 in basal-parabasal 
layers was comparable in the spinous layer irrespective of HPV16 infection (Table 1, Figure 
1).Expression of the tumor suppressor LIMD1 throughout the normal-cervix is indicative of its 
role in maintaining normal cell homeostasis. Similar pattern of LIMD1 expression was observed 
in normal oral epithelium (21). VHL expression is lower in the basal-parabasal layers of normal-
cervix compared to the spinous layer, suggesting it may have a critical role in cellular 
differentiation and proliferation. Similar low expression of VHL was reported in basal-parabasal 
layers of normal-cervix but reduced expression in spinous layer was seen contrary to our data 
(8). High/medium expression of HIF-1α and VEGF in proliferating basal-parabasal layers of 
normal-cervix were seen compared to spinous layer (Table1). Similar, high/medium expression 
of VEGF was reported earlier in the basal-parabasal layers of normal cervical epithelium 
contrary to low expression of HIF-1α (6).No significant difference in expression profiles of these 
genes in normal cervical epithelium were seen with respect to HPV16 infection. Thus, it can be 
suggested that high expression of HIF-1α and its target protein VEGF in basal-parabasal layers 
of normal cervical epitheliums might be due to the reduced expression of VHL. 
 
The expression of LIMD1 and VHL changed differentially during different stages of this tumor 
(Table 1, Figure 1). LIMD1 expression was significantly reduced during stage-wise tumor 
development while VHL expression was comparable (Table 1, Figure 1). This might be due to 
significant increase in methylation frequency of the LIMD1and VHL genes during stage-wise 
development of this tumor. Similar pattern of expression and methylation of LIMD1 was 
reported during development of HNSCC from normal oral epithelium (20,21). Likewise, low 
expression profile of VHL was reported in normal-cervix and CACX (8). Unlike expression 
pattern of LIMD1 and VHL during different stages of CACX, the expression of HIF-1α and 
VEGF were high as seen in basal-parabasal layers of normal-cervix (Table 1, Figure 1). Similar 
expression profiles of HIF-1α and VEGF have also been reported in CACX, HNSCC and 
colorectal cancer (6, 22, 23). The inverse correlation of LIMD1 and VHL expression with that of 
HIF-1α and VEGF was validated by demethylation experiments using 5-aza-dC in HeLa and 
SiHa cell lines (Figure 3). This indicates that up-regulation of both LIMD1 and VHL could lead 
to down-regulation of HIF-1α and its transcriptional target VEGF in the CACX cell lines.   
 
It was evident that during stage-wise development of the tumor, deletions of LIMD1 and VHL 
were seen (Figure 4a,b). Unlike VHL, that had no genetic deletions in CIN and 34-38% deletion 
in invasive tumors, deletion of LIMD1 was evident in CIN (29%) with significant increase in the 
invasive tumors (49-63%) (Figure 4a,b), potentially implicating LIMD1 loss as an early event in 
CACX tumorigenesis, as has been previously observed in lung cancer (24). A similar deletion 
pattern of LIMD1 and VHL was reported during development of HNSCC and breast carcinoma, 
renal cell carcinoma and lung carcinoma (20,25). In addition, the case-control study for 
hmLIMD1 revealed (CA)19 as the risk allele both in its homozygous and heterozygous state for 
stage-wise CACX development. Similar repeat length polymorphism for hmLIMD1 was 
reported earlier in HNSCC (20). It may be suggested that the (CA)19 risk allele might destabilize 
the Z-DNA conformation leading to transcriptional repression of LIMD1. Amplification of HIF-1α 
was absent in our study, while low frequency (9%) of its amplification was reported in HNSCC 
(26). 
The overall alterations (methylation/deletion) of LIMD1 increased significantly from basal-
parabasal layers to CIN and CACX (Fig 4d). While high alteration of VHL in basal-parabasal 
layers was maintained in invasive stages of CACX (Fig 4d). Overall alterations of both LIMD1 
and VHL in CIN/CACX were concordant with their reduced expressions. Both LIMD1, VHL 
gene alterations along-with simultaneous overexpression of genes HIF-1α, VEGF during CACX 
development correlated with poor patient survival (Figure 5), thus raising the possibility that 
alteration of these genes may be used as a diagnostic/prognostic marker in CACX (Fig 5).  
Thus, our data suggest that overexpression of HIF-1α and its transcriptional target VEGF in the 
basal-parabasal layers of normal-cervix was due to frequent inactivation of VHL by its promoter 
methylation. This profile was maintained during different stages of cervical carcinogenesis with 
additional methylation/deletion of VHL and LIMD1.     
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Table 1. Comparative expression (%) pattern of LIMD1, VHL, HIF-1α and VEGF in different 
normal cervical epitheliums, CIN and CACX samples. 
Figure Legends: 
Figure 1. Immunohistochemical expression pattern of LIMD1, VHL, HIF-1α and VEGF in 
disease free normal, HPV16 positive/negative adjacent normal, CIN and CACX samples. 
Arrows point to nuclear/cytoplasmic expression LIMD1, VHL and HIF-1α and 
cytoplasmic/membrane expression of VEGF. Magnification of tissue samples is 20X and for 
inset, magnification is 40X. Scale bars-50 μm D+/-: deletion positive/negative; M+/-: 
methylation positive/negative. 
Figure 2. Promoter methylation analysis of LIMD1 and VHL 
(a).i) Schematic representation of the promoter region of LIMD1 illustrates distribution of HpaII 
(CCGG, marked by arrow head) and HhaI (GCGC, marked by star) restriction sites. The 
positions of primers designed for MSRA are shown by black arrowheads ii) Representative 
tumor sample (#153T) and basal-parabasal layers of corresponding normal showing 
methylated status by MSRA. Corresponding normal cervical tissue and its spinous layer were 
unmethylated. iii) Methylation frequency of LIMD1 observed in different normal cervical 
epitheliums, CIN and CACX stage I/II and III/IV samples. b). i) Schematic representation of the 
promoter region of VHL. ii) Representative tumor sample (#153T) and basal-parabasal layers 
of corresponding normal showing methylated status by MSRA. Corresponding normal cervical 
tissue and its spinous layer were unmethylated. iii) Methylation frequency of VHL observed in 
different normal cervical epitheliums, CIN and CACX stage I/II and III/IV samples. M: Mock, D: 
Digested, K1 (β-3A adaptin gene) and K2 (RARβ2 exon-1): controls for DNA digestion and 
integrity respectively. BP: Basal-parabasal layers, S: Spinous layers.  
Figure 3. Demethylation experiments and Immunocytochemistry in HeLa and SiHa cell lines. 
(a) The mRNA expression of (i) LIMD1 and (ii) VHL were analyzed in HeLa and SiHa cell lines 
after treatment with different concentration (5μm, 10 μm and 20 μm) of 5-aza-dC by QRT-PCR. 
Fold change of mRNA expression was compared with the mRNA of untreated cell line. LIMD1 
and VHL mRNA expressions were up-regulated in a dose dependent manner. 
Immunocytochemical analysis of LIMD1, VHL, HIF-1α and VEGF in (b) HeLa and (c) SiHa : 
LIMD1 and VHL showed up-regulation of cytoplasmic/ nuclear expression after 5-aza-dC 
treatment (ii) compared to untreated cells (i). On the contrary, HIF-1α and VEGF showed 
reduced cytoplasmic/nuclear/membrane expression in treated cells (ii) compared to untreated 
cells (i). Magnification: 40X, Scale bars: 50μm. 
Figure 4. Representative autoradiograph showing Deletion and MA of LIMD1 and VHL  
in different primary cervical lesions. 
(a) i) LIMD1. LOH and MA in different samples ii) Deletion frequency of LIMD1 observed in CIN 
and CACX stage I/II and III/IV samples. (b) i) VHL. LOH and MA in different samples ii) 
Deletion frequency of VHL observed in CIN and CACX stage I/II and III/IV samples and c) 
Representative agarose gel photo showing no amplification in HIF-1α d) Overall alteration 
frequencies of LIMD1 and VHL observed in basal-parabasal epithelium, CIN and CACX stage 
I/II and III/IV samples. LOH, loss of heterozygosity; MA-I, microsatellite size alteration of 1 
allele; MA-II, microsatellite size alteration of both alleles; LMA, LOH+MAI; T: DNA of the 
dysplastic/tumor cells after microdissection; N: DNA of the corresponding normal tissue. 
Figure 5: Clinicopathological Association with overall alterations/expressions of LIMD1, VHL, 
HIF-1α and VEGF.   
A) Kaplan–Meier 5-year survival probability curves with cumulative survival of CACX patients 
by (i) LIMD1 overall alteration, (ii) VHL overall alteration and (iii) LIMD1 and VHL overall 
alteration and  iv-vi) Simultaneous effect of LIMD1, VHL alterations with high expression of 
HIF-1α and VEGF . Survival time was defined as the time from the date of surgery to the date 
of last follow-up, known recurrence or death (up to 5 years). The smooth line represents 
survival probability with molecular alterations and the dotted line represents the same 
probability without molecular alterations. N, total number of CACX samples. b) Multivariate 
analysis of overall survival of cervical cancer patients with different clinicopathological 
parameters and LIMD1, VHL alterations and high expression of HIF-1α, VEGF using Cox 
proportional hazard model. 
Supplementary Legends  
Table S1. Primers for promoter methylation analysis (MSRA) of LIMD1 and VHL. 
Table S2. Primers for promoter methylation analysis (MSP) of LIMD1 and VHL. 
Table S3. Primers for m-RNA expression analysis of LIMD1 and VHL in CACX cell lines. 
Table S4. Primers for copy number variation analyses of LIMD1, VHL and HIF-1α.  
Table S5. Primers for mutation analysis of LIMD1  
Table S6: Relation between expression/methylation of LIMD1, VHL, HIF-1α and VEGF in 
different layers of normal cervical epithelium of control normal (disease free) and normal 
adjacent to CIN and CACX. 
Table S7: Relation between expression of LIMD1 and VHL with expression of HIF-1α and 
VEGF in basal-parabasal layers of normal cervical epithelium, CIN and CACX. H/M: 
High/Medium, L: Low. 
Table S8: Correlation between MSRA and MSP for LIMD1 and VHL. 
Table S9: Allelic Alteration/copy number variation of LIMD1, VHL and HIF-1α in CIN and 
CACX.  
Table S10: Relation between Deletion and expression of LIMD1 and VHL in CIN and CACX. 
Table S11. a) Allele b) Genotype frequency of (CA)n polymorphism in the LIMD1 gene in 
CACX cases and controls. 
Table S12: Relation between expression and alterations of LIMD1 and VHL in CIN and CACX. 
Table S13: Relation between expression and alterations of LIMD1,VHL and HIF-1α , VEGF in 
CIN and CACX.  
Table S14: Relation between expression and alterations of VHL in basal-parabasal layers of 
normal-cervix. 
Table S15: Relation between alteration of LIMD1 and VHL in CIN/CACX.  
Table S16. Expression/methylation/deletion/mutation status of LIMD1,VHL, HIF-1α and VEGF 
in CIN/CACX samples.  
Figure S1. Schematic Distribution of the samples used for this study.  
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